Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Urs E StuderLaurence Collette

Abstract

This study (EORTC 30891) attempted to demonstrate equivalent overall survival in patients with localized prostate cancer not suitable for local curative treatment treated with immediate or deferred androgen ablation. We randomly assigned 985 patients with newly diagnosed prostate cancer T0-4 N0-2 M0 to receive androgen deprivation either immediately (n = 493) or on symptomatic disease progression or occurrence of serious complications (n = 492). Baseline characteristics were well balanced in the two groups. Median age was 73 years (range, 52 to 81). At a median follow-up of 7.8 years, 541 of 985 patients had died, mostly of prostate cancer (n = 193) or cardiovascular disease (n = 185). The overall survival hazard ratio was 1.25 (95% CI, 1.05 to 1.48; noninferiority P > .1) favoring immediate treatment, seemingly due to fewer deaths of nonprostatic cancer causes (P = .06). The time from randomization to progression of hormone refractory disease did not differ significantly, nor did prostate-cancer specific survival. The median time to the start of deferred treatment after study entry was 7 years. In this group 126 patients (25.6%) died without ever needing treatment (44% of the deaths in this arm). Immediate androgen deprivation...Continue Reading

References

Oct 1, 1967·The Journal of Urology
Jan 15, 1997·International Journal of Radiation Oncology, Biology, Physics·A L Zietman, W U Shipley
Aug 19, 2004·JAMA : the Journal of the American Medical Association·Theodore L DeWeese
Oct 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Urs E StuderDaniel Dietrich
Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eeva K SalminenMartti Nurmi

❮ Previous
Next ❯

Citations

Jul 10, 2008·JAMA : the Journal of the American Medical Association·Grace L Lu-YaoSiu-Long Yao
Feb 15, 2008·Der Urologe. Ausg. A·A HeidenreichU H Engelmann
Feb 25, 2010·Der Urologe. Ausg. A·B Wörmann, J M Wolff
Sep 17, 2010·Der Urologe. Ausg. A·A Heidenreich, A J Schrader
Oct 12, 2012·Der Urologe. Ausg. A·M Spahn, K Haeni
May 23, 2013·Der Urologe. Ausg. A·G HatibogluS Pahernik
Dec 10, 2009·Wiener medizinische Wochenschrift·Ingrid BergerStephan Madersbacher
Sep 29, 2011·Wiener medizinische Wochenschrift·Anton PonholzerPaul Schramek
Apr 2, 2009·Current Oncology Reports·Terence W Friedlander, Charles J Ryan
Apr 27, 2007·Current Urology Reports·Ased S M Ali, Freddie C Hamdy
Apr 29, 2010·Current Urology Reports·Mark Garzotto, Arthur Y Hung
Apr 17, 2013·Clinical Oncology : a Journal of the Royal College of Radiologists·D A LoblawUNKNOWN Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care
Dec 4, 2008·Asian Journal of Andrology·Heather Payne
Jan 11, 2012·Asian Journal of Andrology·Roisin M ConnollyEmmanuel S Antonarakis
Feb 25, 2009·Prostate Cancer and Prostatic Diseases·H Van PoppelR Oyen
Jan 11, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HorwichUNKNOWN European Society for Medical Oncology
Dec 10, 2009·Journal of the National Cancer Institute·Nancy L KeatingMatthew R Smith
Apr 7, 2007·Current Opinion in Oncology·Amy M Lin, Eric J Small
Sep 22, 2006·Annual Review of Medicine·Mark Pomerantz, Philip Kantoff
Feb 4, 2010·Circulation·Glenn N LevineUNKNOWN American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer So
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason A EfstathiouMatthew R Smith
Sep 24, 2010·Endocrine-related Cancer·Nima SharifiWilliam L Dahut
Mar 31, 2011·Cancer Management and Research·Hein Van Poppel, Bertrand Tombal
Jun 16, 2011·Urology Annals·Ashraf J AbusamraEyad Al Saeed
Dec 21, 2012·Future Oncology·Guillaume Ploussard, Pierre Mongiat-Artus
May 14, 2014·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·L SalomonM Soulié
Feb 8, 2011·Journal of Endocrinological Investigation·G CoronaM Maggi
Dec 7, 2010·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·L SalomonUNKNOWN Oncology Committee of the French Association of Urology (CCAFU)
Jun 27, 2012·Der Urologe. Ausg. A·A HeidenreichD Pfister
Feb 9, 2012·Current Urology Reports·Alexandre IngelsGuillaume Ploussard
Oct 30, 2007·Der Internist·T JägerC Börgermann
Dec 11, 2013·European Urology·Axel HeidenreichUNKNOWN European Association of Urology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.